ADCK5

Summary

ADCK5 (aarF domain containing kinase 5, HGNC:21738) is a protein-coding gene on chromosome 8q24.3, encoding Uncharacterized aarF domain-containing protein kinase 5 (Q3MIX3). The function of this protein is not yet clear.

Predicted to enable protein serine/threonine kinase activity. Located in mitochondrion.

Source: NCBI Gene 203054 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 145 total — 12 pathogenic, 4 likely-pathogenic
• Druggable target: yes — 2 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_174922

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:21738
Approved symbol	ADCK5
Name	aarF domain containing kinase 5
Location	8q24.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ35454
Ensembl gene	ENSG00000173137
Ensembl biotype	protein_coding
OMIM	621165
Entrez	203054

Gene structure

Transcript identifiers

Ensembl transcripts: 24 — 17 protein_coding, 3 protein_coding_CDS_not_defined, 3 nonsense_mediated_decay, 1 retained_intron

ENST00000308860, ENST00000525136, ENST00000526231, ENST00000526833, ENST00000529654, ENST00000532190, ENST00000533715, ENST00000534714, ENST00000886485, ENST00000886486, ENST00000886487, ENST00000886488, ENST00000886489, ENST00000886490, ENST00000913502, ENST00000913503, ENST00000913504, ENST00000913505, ENST00000913506, ENST00000913507, ENST00000967045, ENST00000967046, ENST00000967047, ENST00000967048

RefSeq mRNA: 1 — MANE Select: NM_174922 NM_174922

CCDS: CCDS34965

Canonical transcript exons

ENST00000308860 — 15 exons

Exon	Start	End
ENSE00001295689	144392969	144393242
ENSE00002195876	144374047	144374107
ENSE00003228407	144391580	144391711
ENSE00003397799	144391783	144391866
ENSE00003473203	144391134	144391274
ENSE00003477672	144390856	144391056
ENSE00003507800	144391361	144391474
ENSE00003516989	144383081	144383230
ENSE00003573301	144392092	144392170
ENSE00003578683	144392776	144392892
ENSE00003593402	144390671	144390746
ENSE00003595410	144392254	144392345
ENSE00003622788	144379387	144379490
ENSE00003637100	144391941	144392022
ENSE00003638157	144392445	144392697

Expression profiles

Bgee: expression breadth ubiquitous, 136 present calls, max score 90.48.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 9.3417 / max 103.1972, expressed in 1778 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
91505	9.0261	1777
91504	0.3156	111

Top tissues by expression

136 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
mucosa of transverse colon	UBERON:0004991	90.48	gold quality
duodenum	UBERON:0002114	88.53	gold quality
right hemisphere of cerebellum	UBERON:0014890	87.00	gold quality
small intestine Peyer’s patch	UBERON:0003454	86.75	gold quality
small intestine	UBERON:0002108	86.28	gold quality
granulocyte	CL:0000094	86.22	gold quality
cerebellar hemisphere	UBERON:0002245	86.22	gold quality
cerebellar cortex	UBERON:0002129	86.13	gold quality
cerebellum	UBERON:0002037	86.08	gold quality
right adrenal gland cortex	UBERON:0035827	85.84	gold quality
left adrenal gland cortex	UBERON:0035825	85.53	gold quality
right adrenal gland	UBERON:0001233	85.37	gold quality
transverse colon	UBERON:0001157	85.11	gold quality
left adrenal gland	UBERON:0001234	84.73	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	84.72	gold quality
lower esophagus mucosa	UBERON:0035834	84.44	gold quality
right lobe of liver	UBERON:0001114	84.09	gold quality
spleen	UBERON:0002106	84.04	gold quality
adrenal gland	UBERON:0002369	83.20	gold quality
apex of heart	UBERON:0002098	82.92	gold quality
intestine	UBERON:0000160	82.90	gold quality
right ovary	UBERON:0002118	82.80	gold quality
colon	UBERON:0001155	82.44	gold quality
esophagus mucosa	UBERON:0002469	82.43	gold quality
right frontal lobe	UBERON:0002810	81.57	gold quality
endocervix	UBERON:0000458	81.56	gold quality
left ovary	UBERON:0002119	81.53	gold quality
body of stomach	UBERON:0001161	81.39	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	81.23	gold quality
vagina	UBERON:0000996	81.23	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-GEOD-100618	yes	48.69
E-ANND-3	yes	3.63
E-MTAB-6075	no	15.16

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

3 targeting ADCK5, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6885-3P	99.75	70.36	3187
HSA-MIR-4690-3P	97.02	64.72	981
HSA-MIR-5685	97.02	64.34	1004

Literature-anchored findings (GeneRIF, showing 1)

• aarF domain containing kinase 5 gene promotes invasion and migration of lung cancer cells through ADCK5-SOX9-PTTG1 pathway. (PMID:32277958)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	adck5	ENSDARG00000075405
mus_musculus	Adck5	ENSMUSG00000022550
rattus_norvegicus	Adck5	ENSRNOG00000030334
drosophila_melanogaster	Adck5	FBGN0036142

Paralogs (4): ADCK1 (ENSG00000063761), COQ8B (ENSG00000123815), ADCK2 (ENSG00000133597), COQ8A (ENSG00000163050)

Protein

Protein identifiers

Uncharacterized aarF domain-containing protein kinase 5 — Q3MIX3 (reviewed: Q3MIX3)

All UniProt accessions (4): Q3MIX3, E9PJ20, E9PLF3, R4GN53

UniProt curated annotations — full annotation on UniProt →

Function. The function of this protein is not yet clear. It is not known if it has protein kinase activity and what type of substrate it would phosphorylate (Ser, Thr or Tyr).

Subcellular location. Membrane.

Similarity. Belongs to the protein kinase superfamily. ADCK protein kinase family.

RefSeq proteins (1): NP_777582* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR004147	ABC1_dom	Domain
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR045307	ADCK1_dom	Domain
IPR051130	Mito_struct-func_regulator	Family

Pfam: PF03109

UniProt features (7 total): sequence conflict 3, chain 1, transmembrane region 1, domain 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q3MIX3-F1	82.08	0.43

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 48 (showing top): TGCGCANK_UNKNOWN, NIKOLSKY_BREAST_CANCER_8Q23_Q24_AMPLICON, GOMF_PROTEIN_KINASE_ACTIVITY, GOMF_KINASE_ACTIVITY, GOMF_PROTEIN_SERINE_THREONINE_KINASE_ACTIVITY, GOMF_TRANSFERASE_ACTIVITY_TRANSFERRING_PHOSPHORUS_CONTAINING_GROUPS, PANGAS_TUMOR_SUPPRESSION_BY_SMAD1_AND_SMAD5_DN, WAKABAYASHI_ADIPOGENESIS_PPARG_RXRA_BOUND_8D, chr8q24, NKX2_3_TARGET_GENES, RYBP_TARGET_GENES, SALL4_TARGET_GENES, SNAI1_TARGET_GENES, UBN1_TARGET_GENES, ZNF561_TARGET_GENES

GO Biological Process (0):

GO Molecular Function (4): protein serine/threonine kinase activity (GO:0004674), protein binding (GO:0005515), kinase activity (GO:0016301), transferase activity (GO:0016740)

GO Cellular Component (2): mitochondrion (GO:0005739), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein kinase activity	1
binding	1
transferase activity, transferring phosphorus-containing groups	1
catalytic activity	1
cytoplasm	1
intracellular membrane-bounded organelle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

942 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ADCK5	FBXL6	Q8N531	605
ADCK5	COQ3	Q9NZJ6	590
ADCK5	COQ4	Q9Y3A0	576
ADCK5	SLC33A2	Q96ES6	556
ADCK5	COQ5	Q5HYK3	555
ADCK5	ADCK2	Q7Z695	523
ADCK5	LRRC14	Q15048	523
ADCK5	MROH1	Q8NDA8	506
ADCK5	CPSF1	Q10570	502
ADCK5	TONSL	Q96HA7	497
ADCK5	COQ2	Q96H96	481
ADCK5	SLC39A4	Q6P5W5	460
ADCK5	COQ6	Q9Y2Z9	459
ADCK5	PPP1R16A	Q96I34	456
ADCK5	COQ9	O75208	451

IntAct

18 interactions, top by confidence:

A	B	Type	Score
NOTCH2NLA	ADCK5	psi-mi:“MI:0915”(physical association)	0.670
ADCK5	NOTCH2NLA	psi-mi:“MI:0915”(physical association)	0.670
ANKRD22	ESYT2	psi-mi:“MI:0914”(association)	0.530
Dlg4	ADCK5	psi-mi:“MI:0407”(direct interaction)	0.440
TNS2	ADCK5	psi-mi:“MI:0915”(physical association)	0.370
HSPA6	ADCK5	psi-mi:“MI:0915”(physical association)	0.370
ADCK5	RHOD	psi-mi:“MI:0915”(physical association)	0.370
Junb	RGPD3	psi-mi:“MI:0914”(association)	0.350
ADCK5	ATP5F1B	psi-mi:“MI:0914”(association)	0.350
ADCK5	AKR1B10	psi-mi:“MI:0914”(association)	0.350
ADCK5	NDUFAB1	psi-mi:“MI:0914”(association)	0.350
ADCK5	ZMPSTE24	psi-mi:“MI:0914”(association)	0.350
LETM1	LETM2	psi-mi:“MI:0914”(association)	0.350
SCN3B	NBAS	psi-mi:“MI:0914”(association)	0.350

BioGRID (18): ADCK5 (Affinity Capture-MS), NOTCH2NL (Two-hybrid), ADCK5 (Two-hybrid), ADCK5 (Affinity Capture-MS), ADCK5 (Affinity Capture-MS), HOGA1 (Affinity Capture-MS), STOML2 (Affinity Capture-MS), CHCHD2 (Affinity Capture-MS), IMMT (Affinity Capture-MS), C1QBP (Affinity Capture-MS), PMPCB (Affinity Capture-MS), ADCK5 (Affinity Capture-MS), ADCK5 (Affinity Capture-MS), TMEM160 (Affinity Capture-MS), ZMPSTE24 (Affinity Capture-MS)

ESM2 similar proteins: A0A172M468, A3QIE3, A8ACY4, A9BP42, A9MY99, B0BU10, B0RLZ0, B0U2R2, B1KR05, B2I583, B2ST34, B2VG47, B3GZD0, B4SZ75, B4TBR5, B4TNY1, B5BIY1, B5EZV0, B5FNW8, B5QW75, B5RFM6, B8F6K1, B9ME24, C0Q3E3, C3K8U2, O42653, O60111, P0A197, P0A198, Q02981, Q06567, Q2P8Q0, Q3BZ34, Q3KJC7, Q3MIX3, Q3YVD0, Q4V052, Q566J8, Q57HN6, Q5H616

Diamond homologs: A0A172M468, A0KEF8, A0L1M6, A1AI24, A1RP80, A1SAK0, A1U669, A3D9F4, A3QIE3, A4STK9, A4WFY3, A4XPM5, A4Y2Q3, A5F4G3, A6WIE7, A7MQL5, A7ZU42, A8A6U2, A8ACY4, A8G8C0, A8H968, A9KYL6, B0RLZ0, B0TJ18, B0U2R2, B1IW70, B1KR05, B1LM23, B1XAJ9, B1XWR5, B2I583, B2ST34, B2TVI6, B2VG47, B3PH50, B5FF80, B5YY84, B6EHA6, B6I4H7, B7L998

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
ADCK5	“up-regulates activity”	SOX9	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

145 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	12
Likely pathogenic	4
Uncertain significance	99
Likely benign	9
Benign	1

Top pathogenic / likely-pathogenic (16)

Variant ID	HGVS	Classification
1454990	NC_000008.10:g.(?144295143)(145701139_?)del	Pathogenic
148271	GRCh38/hg38 8q24.13-24.3(chr8:124498498-145068712)x3	Pathogenic
1527465	GRCh37/hg19 8q24.21-24.3(chr8:130863093-146295771)	Pathogenic
394633	GRCh37/hg19 8q24.22-24.3(chr8:134825277-146280828)x3	Pathogenic
4682719	GRCh37/hg19 8q24.13-24.3(chr8:126446968-146295771)x3	Pathogenic
523293	GRCh37/hg19 8q24.3(chr8:142840194-146280020)	Pathogenic
563531	GRCh37/hg19 8q24.3(chr8:143815037-146295771)x3	Pathogenic
57047	GRCh38/hg38 8q24.3(chr8:144002671-144796947)x3	Pathogenic
686463	GRCh37/hg19 8q24.22-24.3(chr8:136059859-146295771)x3	Pathogenic
689071	GRCh37/hg19 8q24.12-24.3(chr8:122193546-146295771)x3	Pathogenic
815163	GRCh37/hg19 8q24.12-24.3(chr8:121042467-146295771)x3	Pathogenic
815169	GRCh37/hg19 8q24.21-24.3(chr8:128877995-146295771)x3	Pathogenic
148265	GRCh38/hg38 8q24.3(chr8:139004218-145049449)x3	Likely pathogenic
148392	GRCh38/hg38 8q24.3(chr8:139236824-145068712)x3	Likely pathogenic
3384214	Single allele	Likely pathogenic
442205	GRCh37/hg19 8q24.22-24.3(chr8:136378789-146295771)x3	Likely pathogenic

SpliceAI

2299 predictions. Top by Δscore:

Variant	Effect	Δscore
8:144383228:CAGG:C	donor_loss	1.0000
8:144383229:AGGTA:A	donor_loss	1.0000
8:144383230:GGT:G	donor_loss	1.0000
8:144383231:GTAGG:G	donor_loss	1.0000
8:144383232:T:G	donor_loss	1.0000
8:144390842:AT:A	acceptor_gain	1.0000
8:144390843:T:G	acceptor_gain	1.0000
8:144390843:T:TA	acceptor_gain	1.0000
8:144390847:T:A	acceptor_gain	1.0000
8:144390849:T:TA	acceptor_gain	1.0000
8:144391053:GGAG:G	donor_gain	1.0000
8:144391054:G:GT	donor_gain	1.0000
8:144391054:GAGGT:G	donor_loss	1.0000
8:144391055:AGGT:A	donor_loss	1.0000
8:144391056:GGT:G	donor_loss	1.0000
8:144391057:GTG:G	donor_loss	1.0000
8:144391058:T:A	donor_loss	1.0000
8:144391131:CAGG:C	acceptor_loss	1.0000
8:144391132:A:AG	acceptor_gain	1.0000
8:144391132:AG:A	acceptor_gain	1.0000
8:144391132:AGGT:A	acceptor_gain	1.0000
8:144391132:AGGTG:A	acceptor_gain	1.0000
8:144391133:G:GA	acceptor_loss	1.0000
8:144391133:G:GG	acceptor_gain	1.0000
8:144391133:GG:G	acceptor_gain	1.0000
8:144391133:GGT:G	acceptor_gain	1.0000
8:144391133:GGTG:G	acceptor_gain	1.0000
8:144391133:GGTGG:G	acceptor_gain	1.0000
8:144391272:A:T	donor_gain	1.0000
8:144391274:GGTAT:G	donor_loss	1.0000

AlphaMissense

3769 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
8:144391218:A:C	S210R	0.998
8:144391220:C:A	S210R	0.998
8:144391220:C:G	S210R	0.998
8:144391274:G:C	K228N	0.998
8:144391274:G:T	K228N	0.998
8:144392005:A:G	D360G	0.997
8:144392140:A:T	D382V	0.997
8:144390954:G:C	K147N	0.994
8:144390954:G:T	K147N	0.994
8:144391233:C:G	H215D	0.994
8:144392141:C:A	D382E	0.994
8:144392141:C:G	D382E	0.994
8:144390905:C:A	A131D	0.993
8:144391272:A:G	K228E	0.993
8:144391613:T:C	F278L	0.993
8:144391615:C:A	F278L	0.993
8:144391615:C:G	F278L	0.993
8:144392140:A:C	D382A	0.993
8:144392279:T:A	W401R	0.993
8:144392279:T:C	W401R	0.993
8:144390963:G:C	Q150H	0.992
8:144390963:G:T	Q150H	0.992
8:144391270:T:A	V227E	0.992
8:144391634:G:C	A285P	0.992
8:144391790:T:C	L313P	0.992
8:144392006:C:A	D360E	0.992
8:144392006:C:G	D360E	0.992
8:144392021:C:A	N365K	0.992
8:144392021:C:G	N365K	0.992
8:144392626:C:A	N483K	0.992

dbSNP variants (sampled 300 via entrez): RS1000037071 (8:144379294 C>T), RS1000323141 (8:144373060 A>G), RS1000673675 (8:144373328 T>C), RS1001094363 (8:144377624 G>A), RS1001325200 (8:144385243 G>A), RS1001364441 (8:144393113 T>C), RS1001535833 (8:144388250 G>A,C,T), RS1001758144 (8:144382497 A>G,T), RS1001943346 (8:144374606 C>T), RS1002398784 (8:144374344 C>T), RS1002504892 (8:144371382 C>A), RS1003435139 (8:144383432 C>T), RS1003664988 (8:144375503 A>G), RS1003920382 (8:144391867 G>A,C,T), RS1004150617 (8:144386046 T>C)

Disease associations

OMIM: gene MIM:621165 | disease phenotypes: MIM:131950, MIM:226670, MIM:612138, MIM:613723, MIM:616487, MIM:236100, MIM:614707, MIM:179613

GenCC curated gene-disease

Mondo (9): epidermolysis bullosa simplex 5A, Ogna type (MONDO:0007555), epidermolysis bullosa simplex 5B, with muscular dystrophy (MONDO:0009181), epidermolysis bullosa simplex 5C, with pyloric atresia (MONDO:0012807), autosomal recessive limb-girdle muscular dystrophy type 2Q (MONDO:0013390), epidermolysis bullosa simplex with nail dystrophy (MONDO:0014661), holoprosencephaly (MONDO:0016296), Brown-Vialetto-van Laere syndrome 2 (MONDO:0013867), recombinant 8 syndrome (MONDO:0008365), intellectual disability (MONDO:0001071)

Orphanet (9): Epidermolysis bullosa simplex with pyloric atresia (Orphanet:158684), Holoprosencephaly (Orphanet:2162), Plectin-related limb-girdle muscular dystrophy R17 (Orphanet:254361), Epidermolysis bullosa simplex with muscular dystrophy (Orphanet:257), PLEC-related intermediate epidermolysis bullosa simplex without extracutaneous involvement (Orphanet:79401), RFVT3-related riboflavin transporter deficiency (Orphanet:572550), Riboflavin transporter deficiency (Orphanet:97229), Recombinant 8 syndrome (Orphanet:96167), NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST003981_3	Insomnia	7.000000e-08

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0007876	insomnia measurement

MeSH disease descriptors (6)

Descriptor	Name	Tree numbers
D016142	Holoprosencephaly	C05.660.207.410; C10.500.034.875; C16.131.077.410; C16.131.260.380; C16.131.621.207.410; C16.131.666.034.875; C16.320.180.380
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539
C535955	Epidermolysa bullosa simplex and limb girdle muscular dystrophy (supp.)
C567408	Epidermolysis Bullosa Simplex With Pyloric Atresia (supp.)
C535962	Epidermolysis bullosa simplex, Ogna type (supp.)
C535296	Recombinant chromosome 8 syndrome (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4105886 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

2 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 10,850 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL180022	NERATINIB	4	9,404
CHEMBL1091644	LINSITINIB	3	1,446

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — ABC1-B subfamily

ChEMBL bioactivities

2 potent at pChembl≥5 of 3 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.70	Kd	202	nM	LINSITINIB
6.10	Kd	796	nM	NERATINIB

PubChem BioAssay actives

2 with measured affinity, of 143 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol	1424906: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.2020	uM
Neratinib	1424906: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.7960	uM

CTD chemical–gene interactions

10 total (human), top 10 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Tobacco Smoke Pollution	decreases expression, affects expression	2
ferrous chloride	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
abrine	decreases expression	1
jinfukang	increases expression, affects cotreatment	1
Arsenic	affects methylation	1
Cisplatin	increases expression, affects cotreatment	1
Hydrogen Peroxide	affects expression	1
Smoke	decreases expression	1
Acrylamide	decreases expression	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3991619	Binding	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by ma	The target landscape of clinical kinase drugs. — Science

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_SB65	HAP1 ADCK5 (-) 1	Cancer cell line	Male
CVCL_SB66	HAP1 ADCK5 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

202 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05744479	PHASE4	RECRUITING	Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06107829	PHASE4	WITHDRAWN	Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
NCT06997198	PHASE4	NOT_YET_RECRUITING	Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
NCT02270736	PHASE3	COMPLETED	Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NCT02304302	PHASE2	COMPLETED	Down Syndrome Memantine Follow-up Study
NCT03862950	PHASE2	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome (Met)
NCT04529226	PHASE2	UNKNOWN	Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
NCT04821856	PHASE2	COMPLETED	Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability
NCT05273320	PHASE1	COMPLETED	Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities
NCT05301361	PHASE1	ENROLLING_BY_INVITATION	Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities
NCT06016764	PHASE1	COMPLETED	Use of MRI and cTBS for Catatonia in Autism
NCT06586827	PHASE1	COMPLETED	Impact of Competency-Based Training and Technical Assistance Employment Outcomes of Individuals With ID/DD
NCT07531940	PHASE1	NOT_YET_RECRUITING	Escalating Doses of Memantine in Down Syndrome (MEDS-123)
NCT05989620	Not specified	RECRUITING	Long-Term Development of Muscular Dystrophy Outcome Assessments
NCT00005016	Not specified	COMPLETED	Study of the Experiences and Needs of Parents Continuing a Pregnancy Following a Prenatal Diagnosis of Holopresencephaly
NCT00088426	Not specified	COMPLETED	Clinical and Genetic Studies on Holoprosencephaly
NCT00645645	Not specified	COMPLETED	A Study of the Genetic Analysis of Brain Disorders
NCT04691414	Not specified	COMPLETED	Retrospective Study Using Next Generation Sequencing (NGS) on Biological Samples to Improve Genetic Counseling for Patients With Previously Explored Craniofacial Midline Defects.
NCT03479476	PHASE2/PHASE3	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome
NCT02616796	PHASE1/PHASE2	COMPLETED	Effects of Social Gaze Training on Brain and Behavior in Fragile X Syndrome
NCT06860672	EARLY_PHASE1	RECRUITING	Clinical Trial of the Dual Vector Base Editor for the Treatment of the CHD3-R1025W Mutation
NCT00597948	Not specified	COMPLETED	Healthy Lifestyles for People With Intellectual Disabilities
NCT01087320	Not specified	RECRUITING	Genome Medical Sequencing for Gene Discovery
NCT01652963	Not specified	UNKNOWN	Picture-based Computerised Assessment and Training of Cognitive Behaviour Therapy Skills
NCT01695395	Not specified	COMPLETED	Mental Health Care Provision for Adults With Intellectual Disability and a Mental Disorder
NCT01867554	Not specified	COMPLETED	Research and Characterization of New Genes Involved in Intellectual Disability
NCT01915381	Not specified	COMPLETED	Improving Adherence Healthy Lifestyle With a Smartphone Application Based on Adults With Intellectual Disabilities
NCT01988623	Not specified	COMPLETED	Pivotal Response Treatment for Individuals With Intellectual Disabilities
NCT02099773	Not specified	COMPLETED	Support Staff-client Interactions With Augmentative and Alternative Communication
NCT02136849	Not specified	COMPLETED	Inter-regional Project of the Great Western Exploration Approach for Exome Molecular Causes Severe Intellectual Disability Isolated or Syndromic
NCT02225041	Not specified	COMPLETED	Sedation Strategy and Cognitive Outcome After Critical Illness in Early Childhood
NCT02414438	Not specified	COMPLETED	Establishing the Clinical Utility of First StepDx PLUS and NextStepDx PLUS Study
NCT02451761	Not specified	COMPLETED	Apparently Balanced Chromosomal Translocation/ Next-generation Sequencing/ Intellectual Disability
NCT02461420	Not specified	ACTIVE_NOT_RECRUITING	Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome
NCT02461459	Not specified	ACTIVE_NOT_RECRUITING	Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)
NCT02486081	Not specified	COMPLETED	Development and Application-Smart Football for Movement Evaluation and Training in the Special Education Population
NCT02504502	Not specified	COMPLETED	Enhancing Genomic Laboratory Reports to Enhance Communication and Empower Patients
NCT02513277	Not specified	COMPLETED	Diabetes Screening & Prevention for People With Learning (Intellectual) Disabilities:STOP Diabetes Study
NCT02561754	Not specified	COMPLETED	Weight Management for Adolescents With IDD